• Test Code:
    1610
  • Department:
  • Test Synonyms:
    Heterotaxy SyndromeACVR2BARMC4C21ORF59CCDC103CCDC114CCDC151CCDC39CCDC40CCDC65CCNOCENPFCITED2CRELD1DNAAF1DNAAF2DNAAF3DNAH11DNAH5DNAI1DNAI2DNAJB13DRC1DYX1C1FOXH1GAS8GATA4GDF1HEATR2LEFTY2LRRC6NKX2-5NODALPIH1D3RSPH1RSPH3RSPH4ARSPH9SHROOM3SMAD2SPAG1ZIC3ZMYND10
  • CPT Code(s):
    81479
Background:

Heterotaxy is a congenital condition diagnosed by abnormal arrangement of organs in the chest and abdomen. The arrangements of the organs are flipped where they are typically seen, a condition called situs inversus or situs amiguus. This mis-orientation may cause structural abnormalities of the organs.  The prevalence of these conditions is about 1:10,000 worldwide. These conditions may be sporadic or follow an autosomal dominant, recessive or X-linked pattern. This next-generation sequencing test assesses the coding regions of 42 genes associated with heterotaxy syndrome. 

Reasons for Referral:

  • Confirm a clinical diagnosis for a genetic etiology for heterotaxia
  • Carrier testing
  • Positive family history

Methodology:

Next generation sequencing (NGS) will analyze the exons or coding regions of the genes using Illumina NextSeq 500/550 technology and preparing samples using hybridization probes to enrich exonic regions.  This assay does not assess regions of insufficient coverage, introns and promoter regions; pseudogenes; where the reference genome is inaccurate or contains gaps and insertions; and regions of high GC or polynucleotide repeats, but may contain variants that impact gene function.

Exon-level deletion/duplication analysis is performed by running the NGS data through the Genome Analysis Toolkit (GATK) Germline Copy Number Variation best practices pipeline from GATK, version 4.1.4.1. A Bayesian model was validated clinically in our lab. The model can detect copy changes at a resolution of three (3) or more probe targets (exons) for deletions and duplications in genes that do not have pseudogenes, and is not designed to detect low-level mosaicism or balanced alterations.

 

The 42 Heterotaxia-associated genes are listed below:
ACVR2B, ARMC4, C21ORF59, CCDC103, CCDC114,  CCDC151, CCDC39, CCDC40, CCDC65, CCNO, CENPF, CITED2, CRELD1, DNAAF1, DNAAF2, DNAAF3, DNAH11, DNAH5, DNAI1, DNAI2, DNAJB13, DRC1, DYX1C1, FOXH1, GAS8, GATA4, GDF1, HEATR2, LEFTY2, LRRC6, NKX2-5, NODAL, PIH1D3, RSPH1, RSPH3, RSPH4A, RSPH9, SHROOM3, SMAD2, SPAG1, ZIC3, ZMYND10

Specimen Requirements:

Blood:  EDTA or ACD (Solution A or B):

  • Adult: 5 mL
  • Child: 5 mL
  • Infant: 2-3 mL

Saliva: 2 ORAgene™ Saliva Collection Kit(s) (OGR-500). Please contact KDL Client Services for a Saliva Collection Kit for patients that cannot provide a blood sample.

Assisted Saliva: 4 ORAgene™ Assisted Saliva Collection Kit(s) (OGR-575) used according to manufacturer instructions.  Please contact KDL Client Services for a Saliva Collection Kit for patients that cannot provide a blood sample.

Skin Fibroblast: Punch Biopsy (Cell cultures will be prepared at KDL and used for testing), or 2 T-25 confluent flasks.

Prenatal:

  • Direct Amniotic Fluid (10-20mL)
  • Direct CVS
  • Direct POC
  • Cultured Amniocytes (2 T-25 flasks)
  • Cultured CVS (2 T-25 flasks)
  • Cultured Fetal Tissue: Product of Conception (2 T-25 flasks)
  • Cord Blood (1-2mL)
  • DNA: 10µg at a minimum of 60-100ng/µL (DNA must be extracted in a CLIA-certified laboratory or a laboratory meeting equivalent requirements as determined by the CAP and/or CMS)


    Notice Regarding Molecular Genetic Testing on Prenatal Specimens:

    • Maternal cell rule-out testing will be performed on all prenatal specimens received. Please provide maternal blood (or saliva) in addition to the fetal specimen. Additional charges apply for the maternal cell rule-out test.
    For routine testing of blood and saliva (or DNA extracted from them), KDL does NOT accept samples from patients within two (2) weeks of a packed cell/platelet transfusion or within four (4) weeks of a whole blood transfusion.  For extraordinary circumstances, where testing must be performed outside of the above windows, please contact our lab.


    A REQUISITION FORM MUST ACCOMPANY ALL SAMPLES.  Please include detailed clinical information, including ethnicity, clinical history, and family history.

    Test Performed (Days):

    Weekly

    Turn Around Time:

    8 weeks

    Shipment Sensitivity Requirements:

    • Package and ship specimen to remain cold, but not frozen. 
    • Ship via overnight express, using the FedEx priority overnight label provided. 
    • Contact Client Services for shipping kits and instructions at (855) 535-1522.

    References:

    1. Genetics Home Reference: Heterotaxy Syndrome https://ghr.nlm.nih.gov/condition/heterotaxy-syndrome#

    Additional Info:

    The Knight Cancer Institute at Oregon Health & Science University is a pioneer in the field of precision cancer medicine. The institute's director, Brian Druker, M.D., helped prove it was possible to shut down just the cells that enable cancer to grow. This breakthrough has made once-fatal forms of the disease manageable and transformed how cancer is treated. The OHSU Knight Cancer Institute is the only National Cancer Institute-designated Cancer Center between Sacramento and Seattle – an honor earned only by the nation's top cancer centers. It is headquarters for one of the National Cancer Institute's largest research collaboratives, SWOG, in addition to offering the latest treatments and technologies as well as hundreds of research studies and clinical trials.

    Learn More